Literature DB >> 34473959

CDNF: An innovative actor in disease-modifying approaches for Parkinson's disease.

Liliane Tenenbaum1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34473959      PMCID： PMC8417500          DOI： 10.1016/j.ymthe.2021.08.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   12.910


× No keyword cloud information.
  10 in total

1.  A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture.

Authors:  A Carlsson
Journal:  Biosci Rep       Date:  2001-12       Impact factor: 3.840

Review 2.  An ERcentric view of Parkinson's disease.

Authors:  Gabriela Mercado; Pamela Valdés; Claudio Hetz
Journal:  Trends Mol Med       Date:  2013-01-24       Impact factor: 11.951

3.  GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons.

Authors:  Piotr Chmielarz; Şafak Er; Julia Konovalova; Laura Bandres; Irena Hlushchuk; Katrina Albert; Anne Panhelainen; Kelvin Luk; Mikko Airavaara; Andrii Domanskyi
Journal:  Mov Disord       Date:  2020-09-16       Impact factor: 10.338

4.  Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation.

Authors:  P Limousin; P Pollak; A Benazzouz; D Hoffmann; J F Le Bas; E Broussolle; J E Perret; A L Benabid
Journal:  Lancet       Date:  1995-01-14       Impact factor: 79.321

Review 5.  Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.

Authors:  Merja H Voutilainen; Urmas Arumäe; Mikko Airavaara; Mart Saarma
Journal:  FEBS Lett       Date:  2015-10-09       Impact factor: 4.124

Review 6.  Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.

Authors:  Liliane Tenenbaum; Marie Humbert-Claude
Journal:  Front Neuroanat       Date:  2017-04-10       Impact factor: 3.856

7.  Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.

Authors:  Merja H Voutilainen; Francesca De Lorenzo; Polina Stepanova; Susanne Bäck; Li-Ying Yu; Päivi Lindholm; Eeva Pörsti; Mart Saarma; Pekka T Männistö; Raimo K Tuominen
Journal:  eNeuro       Date:  2017-03-13

Review 8.  The Synucleinopathies: Twenty Years On.

Authors:  Michel Goedert; Ross Jakes; Maria Grazia Spillantini
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

9.  The Future of GDNF in Parkinson's Disease.

Authors:  Fredric P Manfredsson; Nicole K Polinski; Thyagarajan Subramanian; Nicholas Boulis; Dustin R Wakeman; Ronald J Mandel
Journal:  Front Aging Neurosci       Date:  2020-12-07       Impact factor: 5.750

10.  Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo.

Authors:  Katrina Albert; Diana P Raymundo; Anne Panhelainen; Ave Eesmaa; Liana Shvachiy; Gabriela R Araújo; Piotr Chmielarz; Xu Yan; Aastha Singh; Yraima Cordeiro; Fernando L Palhano; Debora Foguel; Kelvin C Luk; Andrii Domanskyi; Merja H Voutilainen; Henri J Huttunen; Tiago F Outeiro; Mart Saarma; Marcius S Almeida; Mikko Airavaara
Journal:  Mol Ther       Date:  2021-05-01       Impact factor: 12.910
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.